The serum pentraxin-3 is elevated in patients with cardiac syndrome X

被引:12
作者
Buyukkaya, Eyup [1 ]
Karakas, Mehmet Fatih [1 ]
Kurt, Mustafa [1 ]
Motor, Sedat [2 ]
Akcay, Adnan Burak [1 ]
Buyukkaya, Sule [4 ]
Karakas, Esra [3 ]
Sen, Nihat [1 ]
机构
[1] Mustafa Kemal Univ, Tayfur Ata Sokmen Fac Med, Dept Cardiol, Antakya, Turkey
[2] Mustafa Kemal Univ, Tayfur Ata Sokmen Fac Med, Dept Clin Biochem, Antakya, Turkey
[3] Mustafa Kemal Univ, Tayfur Ata Sokmen Fac Med, Dept Endocrinol & Metab, Antakya, Turkey
[4] Antakya State Hosp, Dept Cardiol, Antakya, Turkey
来源
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY | 2013年 / 41卷 / 04期
关键词
Angina pectoris/etiology; cardiac syndrome X; C-reactive protein; coronary angiography; coronary artery disease; PTX3; protein; syndrome;
D O I
10.5543/tkda.2013.20025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Cardiac syndrome X (CSX) is a clinical entity that is defined as normal coronary arteries with angina pectoris and objective sins of ischemia. The correlation between CSX and inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) is well established, however an association with pentraxin-3 (PTX-3) has not been examined. The aim of this study was to investigate the association between PTX-3 and CSX. Study design: A total of 122 patients (58 female, 64 male, mean age 49.6 +/- 5.8 years) with suspected of coronary artery disease (CAD) were included in the study. Those with evidence of ischemia (50 patients with positive treadmill tests, 32 patients with positive myocardial perfusion scintography) underwent coronary angiography (82 patients). Patients with a normal angiogram were considered the CSX group (n=41) and patients with coronary lesions were referred to as the CAD group (n=41). Patients without signs of ischemia served as the control group. Serum PTX-3 and hs-CRP levels were measured in all patients. Results: The CSX group had significantly increased PTX-3 levels relative to the control group (0.46 +/- 0.16 vs. 0.23 +/- 0.09 ng/ml, p<0.001). However there were no differences in levels of PTX-3 and hs-CRP between the CSX and the CAD groups (PTX-3: 0.46 +/- 0.16 vs. 0.51 +/- 0.13 ng/ml, p=0.21; hs-CRP: 1.04 +/- 0.45 vs. 1.16 +/- 0.64 mg/dl, p=0.62). The control group had significantly lower hs-CRP levels (0.73 +/- 0.51 mg/dl) when compared to the both CSX and CAD groups (p=0.03 and p=0.002, respectively). Serum PTX-3 levels were weakly correlated with hs-CRP levels (r=0.30, p=0.001). Conclusion: PTX-3, a novel inflammatory marker, is elevated in patients with CSX, similar to the well known inflammatory marker hs-CRP, and may be a promising biomarker reflecting inflammatory status in these patients.
引用
收藏
页码:290 / 295
页数:6
相关论文
共 29 条
  • [1] Bevelacqua V, 2006, INT J MOL MED, V18, P415
  • [2] The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity
    Bottazzi, Barbara
    Garlanda, Cecilia
    Cotena, Alessia
    Moalli, Federica
    Jaillon, Sebastien
    Deban, Livija
    Mantovani, Alberto
    [J]. IMMUNOLOGICAL REVIEWS, 2009, 227 : 9 - 18
  • [3] White blood cell count: An independent predictor of coronary heart disease mortality among a national cohort
    Brown, DW
    Giles, WH
    Croft, JB
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2001, 54 (03) : 316 - 322
  • [4] Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo
    Camozzi, M
    Zacchigna, S
    Rusnati, M
    Coltrini, D
    Ramirez-Correa, G
    Bottazzi, B
    Mantovani, A
    Giacca, M
    Presta, M
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (09) : 1837 - 1842
  • [5] C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms
    Cosín-Sales, J
    Pizzi, C
    Brown, S
    Kaski, JC
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (09) : 1468 - 1474
  • [6] Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: Data from the Heart and Soul Study
    Dubin, Ruth
    Li, Yongmei
    Ix, Joachim H.
    Shlipak, Michael G.
    Whooley, Mary
    Peralta, Carmen A.
    [J]. AMERICAN HEART JOURNAL, 2012, 163 (02) : 274 - 279
  • [7] EVIDENCE OF IMPAIRED ENDOTHELIUM-DEPENDENT CORONARY VASODILATATION IN PATIENTS WITH ANGINA-PECTORIS AND NORMAL CORONARY ANGIOGRAMS
    EGASHIRA, K
    INOU, T
    HIROOKA, Y
    YAMADA, A
    URABE, Y
    TAKESHITA, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (23) : 1659 - 1664
  • [8] Fazzini F, 2001, ARTHRITIS RHEUM, V44, P2841, DOI 10.1002/1529-0131(200112)44:12<2841::AID-ART472>3.0.CO
  • [9] 2-6
  • [10] Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease
    Fichtlscherer, S
    Rosenberger, G
    Walter, DH
    Breuer, S
    Dimmeler, S
    Zeiher, AM
    [J]. CIRCULATION, 2000, 102 (09) : 1000 - 1006